MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamaneurol.2020.2703

Медицинская библиотека · JAMA neurology · 2020

Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.

Rubin Daniel B, Al Jarrah Ali, Li Karen, LaRose Sarah, Monk Andrew D, Ali Ali Basil, Spendley Lauren N, Nikiforow Sarah, Jacobson Caron, Vaitkevicius Henrikas

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

IMPORTANCE

Chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory hematologic malignant neoplasm causes severe neurologic adverse events ranging from encephalopathy and aphasia to cerebral edema and death. The cause of neurotoxicity is incompletely understood, and its unpredictability is a reason for prolonged hospitalization after CAR T-cell infusion.

OBJECTIVE

To identify clinical and laboratory parameters predictive of neurotoxicity and to develop a prognostic score associated with its risk.

DESIGN, SETTING, AND

PARTICIPANTS

This single-center diagnostic/prognostic accuracy study was conducted at Brigham and Women's Hospital/Dana Farber Cancer Institute from April 2015 to February 2020. A consecutive sample of all patients undergoing CAR T-cell therapy with axicabtagene ciloleucel for relapsed or refractory lymphoma were assessed for inclusion (n = 213). Patients who had previously received CAR T cells or who were treated for mantle cell lymphoma were excluded (n = 9). Patients were followed up for a minimum of 30 days from the date of CAR T-cell infusion.

MAIN OUTCOMES AND MEASURES: The primary outcomes were measures of performance (accuracy, sensitivity, specificity, area under the curve) of a diagnostic tool to predict the occurrence of CAR-associated neurotoxicity, as graded by the Common Terminology Criteria for Adverse Events criteria.

RESULTS

Two hundred four patients (127 men [62.2%]; mean [SD] age, 60.0 [12.1] years) were included in the analysis, of which 126 (61.8%) comprised a derivation cohort and 78 (38.2%), an internal validation cohort. Seventy-three patients (57.9%) in the derivation cohort and 45 patients (57.7%) in the validation cohort experienced neurotoxicity. Clinical and laboratory values obtained early in admission were used to develop a multivariable score that can predict the subsequent development of neurotoxicity; when tested on an internal validation cohort, this score had an area under the curve of 74%, an accuracy of 77%, a sensitivity of 82%, and a specificity of 70% (positive:negative likelihood ratio, 2.71:0.26).

CONCLUSIONS AND RELEVANCE: The score developed in this study may help predict which patients are likely to experience CAR T-cell-associated neurotoxicity. The score can be used for triaging and resource allocation and may allow a large proportion of patients to be discharged from the hospital early.

Для цитирования: Rubin Daniel B, Al Jarrah Ali, Li Karen, LaRose Sarah, Monk Andrew D, Ali Ali Basil, Spendley Lauren N, Nikiforow Sarah, Jacobson Caron, Vaitkevicius Henrikas. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.. JAMA neurology. 2020. DOI: 10.1001/jamaneurol.2020.2703.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.